Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Cisplatin 294Radiotherapy 230Fluorouracil 201Cyclophosphamide 191Capecitabine 182Docetaxel 166Gemcitabine 165Oxaliplatin 162Carboplatin 160Paclitaxel 152Leucovorin 122Drug Therapy 118Dexamethasone 118Doxorubicin 112Etoposide 99Bevacizumab 91Cytarabine 87Vincristine 83Irinotecan 81Rituximab 77Epirubicin 71Prednisone 65Radiosurgery 63Methotrexate 62Surgical Procedures, Operative 61Radiation 60Radiotherapy, Intensity-Modulated 56Neoadjuvant Therapy 53Lenalidomide 52Letrozole 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER × Furosemide × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡